Innate Pharma S.A.
IPHA
$1.93
-$0.04-2.03%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.33M | -13.44M | -5.00M | -5.05M | 935.00K |
| Total Depreciation and Amortization | 614.60K | 619.90K | 778.40K | 786.90K | 1.98M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.80K | 33.10K | 166.90K | 168.70K | 926.30K |
| Change in Net Operating Assets | 14.31M | 14.44M | -7.30M | -7.38M | -10.08M |
| Cash from Operations | 1.63M | 1.65M | -11.35M | -11.48M | -6.24M |
| Capital Expenditure | -152.30K | -153.60K | -22.60K | -22.90K | -168.20K |
| Sale of Property, Plant, and Equipment | -- | -- | 80.70K | 81.60K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 653.90K | 659.50K | 11.18M | 11.30M | 34.30K |
| Cash from Investing | 501.60K | 505.90K | 11.24M | 11.36M | -133.90K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.21M | -2.21M | -383.50K | -383.50K | -797.00K |
| Issuance of Common Stock | 46.50K | 46.50K | 23.50K | 23.50K | 174.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.33M | -2.35M | -387.60K | -391.80K | -678.10K |
| Foreign Exchange rate Adjustments | -138.30K | -139.50K | 69.40K | 70.20K | 78.90K |
| Miscellaneous Cash Flow Adjustments | 500.00 | 500.00 | -500.00 | -500.00 | 500.00 |
| Net Change in Cash | -331.00K | -333.80K | -434.90K | -439.70K | -6.97M |